|1.||Wei, Wei: 4 articles (05/2013 - 03/2011)|
|2.||Nestorov, I: 4 articles (01/2010 - 01/2008)|
|3.||Tak, P P: 3 articles (11/2015 - 01/2008)|
|4.||Wu, Yujing: 3 articles (05/2013 - 05/2011)|
|5.||Zhang, Lingling: 3 articles (05/2013 - 03/2011)|
|6.||Chang, Yan: 3 articles (05/2013 - 05/2011)|
|7.||Dillon, S R: 3 articles (12/2008 - 04/2000)|
|8.||Mudri, S: 3 articles (12/2008 - 04/2000)|
|9.||Gross, J A: 3 articles (12/2008 - 04/2000)|
|10.||Nestorov, Ivan: 3 articles (04/2008 - 07/2007)|
07/01/2011 - "The Atacicept for Reduction of Signs and Symptoms in Rheumatoid Arthritis Trial (AUGUST I) was a multicenter, phase II, double-blind, placebo-controlled dose-finding study involving 256 patients randomized 1:1:1:1 to receive atacicept (25 mg, 75 mg, or 150 mg) or placebo twice weekly for 4 weeks, then weekly for 21 weeks, with a 13-week treatment-free followup period (week 38). "
04/01/2008 - "Atacicept pharmacokinetics and pharmacodynamics were assessed in a double-blind, placebo-controlled, phase I study in patients with active, moderate to severe rheumatoid arthritis receiving atacicept either as a single subcutaneous or repeated, every other week dose. "
01/01/2008 - "The purpose of this study was to investigate the tolerability, pharmacokinetics, and pharmacodynamics of atacicept treatment in patients with rheumatoid arthritis (RA) and to collect exploratory data on clinical outcomes. "
01/01/2008 - "Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study."
09/01/2014 - "Atacicept as an investigated therapy for rheumatoid arthritis."
|2.||Autoimmune Diseases (Autoimmune Disease)
04/27/2000 - "These findings demonstrate the involvement of zTNF4 and its receptors in the development of SLE and identify TACI-Ig as a promising treatment of autoimmune disease in humans."
01/01/2013 - "Atacicept, another biologic inhibiting BLyS and APRIL, was terminated for serious adverse events--raising the question of whether APRIL should be neutralized in autoimmune diseases."
01/01/2006 - "Because of these activities, TACI-Ig is in clinical evaluation for treatment of various autoimmune diseases and B cell malignancies. "
08/01/2001 - "TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. "
07/01/2010 - "The efficacy of atacicept in animal models of autoimmune disease and the biological activity of atacicept in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) has been demonstrated. "
|3.||Systemic Lupus Erythematosus (Libman-Sacks Disease)
11/01/2015 - "Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)."
01/01/2010 - "Pharmacokinetics (PKs) and biological activity of intravenous (iv) and subcutaneous (sc) atacicept are described here for patients with systemic lupus erythematosus in two randomized, double-blind, placebo-controlled, Phase Ib studies. "
05/01/2009 - "An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus."
01/01/2015 - "Profile of atacicept and its potential in the treatment of systemic lupus erythematosus."
01/15/2015 - "However, disease activity in multiple sclerosis unexpectedly increased, whereas in systemic lupus erythematosus, atacicept was beneficial. "
05/01/2011 - "TACI-Ig (2.1, 6.3 mg/kg) treatment significantly reduced the severity of established arthritis using the methods of clinical observation and histopathological examination. "
12/01/2011 - "The objective of this study was to investigate immunoregulatory efficacy of TACI-Ig on helper T (Th) cells in mesenteric lymph node (MLN) of adjuvant-induced arthritis (AA) in rats. "
12/01/2011 - "TACI-Ig induces immune balance of Th cells in MLN via BLyS/APRIL-receptors signaling in rats with adjuvant-induced arthritis."
05/01/2011 - "Therapeutic effects of TACI-Ig on rats with adjuvant-induced arthritis via attenuating inflammatory responses."
02/01/2011 - "Administration of TACI-Ig significantly reduced the arthritis global assessment and SJC, decreased spleen index and ameliorated histopathological manifestations of rat AA. "
03/11/2011 - "Further studies showed that TACI-Ig inhibited T and B lymphocyte proliferation response, and inhibited differentiation and activity of T and B lymphocytes in collagen-induced arthritis mice. "
05/01/2011 - "Data presented here demonstrate that administration of TACI-Ig significantly attenuates progression of experimental arthritis, with reductions in inflammatory response and bone and joint destruction."
03/11/2011 - "To investigate the abnormal function of T and B lymphocytes involved in collagen-induced arthritis in DBA/1 mice and the regulation role of TACI-Ig on T and B lymphocytes, collagen-induced arthritis models were established in DBA/1 mice. "
03/11/2011 - "Therapeutic effects of TACI-Ig on collagen-induced arthritis by regulating T and B lymphocytes function in DBA/1 mice."
02/01/2011 - "Therapeutic effects of TACI-Ig on rat with adjuvant arthritis."
|1.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|5.||Immunoglobulin G (IgG)
|6.||Immunoglobulin M (IgM)
|7.||Carrier Proteins (Binding Protein)
|8.||Adrenal Cortex Hormones (Corticosteroids)
|9.||mycophenolate mofetil (Cellcept)
|10.||B-Cell Activating Factor
|2.||Drug Therapy (Chemotherapy)